| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of ...
Based on the company's current operating plan, the company projects current cash, cash equivalents and marketable securitie...
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target fro...
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $36 to $46.
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced p...
Raymond James analyst Laura Prendergast upgrades Revolution Medicines (NASDAQ:RVMD) from Outperform to Strong Buy and raises...
Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the di...
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
